An Extensive Breakdown of the Pharmaceutical and Biologics Landscape

Wayne chats with Daniel Kracov, Partner and Chair of the Life Sciences Industry Group at Arnold & Porter, and Dr. Gayatri Rao, Director at Hyman, Phelps & McNamara. You'll hear their thoughts on Operation TrialBlazer; what's been happening lately with CBER and CDER; the latest in rare diseases and orphan drugs; developments in cell and gene therapy; the Plausible Mechanism Framework; the situation with China and global drug development; and much more.  In our headlines segment, Wayne highlights these major developments:  Acting FDA Commissioner Kyle Diamantas releases new strategic framework built around four public health priorities  Pharma: FDA makes 14 CRLs available, rejecting drug applications, despite previously pausing real-time CRL transparency initiative Devices: FDA clears Software as a Medical Device with patient-facing LLM Food: FDA delays publication of proposed rule to eliminate the GRAS pathway  Cosmetics: PCPC urges U.S. Trade Representative to ensure cosmetics and personal care products are prioritized in proposed U.S.-China Board of Trade In our Resource Links segment, we list key documents in our four core areas. To view <span class= "NormalTextRun SCXW